This study will test the feasibility, safety, and evidence for efficacy of psilocybin administration in participants with obsessive compulsive disorder (OCD). This will serve as a preliminary proof of concept study for future larger studies aimed to investigate the utility, cognitive mechanisms, and neural correlates of this intervention.
4 Primary · 0 Secondary · Reporting Duration: 1 month post session 2
Active Control
Experimental Treatment
30 Total Participants · 2 Treatment Groups
Primary Treatment: Immediate Psilocybin · No Placebo Group · Phase < 1
Age 21 - 70 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Maryland | 33.3% |
New Jersey | 33.3% |
California | 33.3% |
Johns Hopkins University School of Medicine | 100.0% |
Met criteria | 100.0% |
0 | 100.0% |